viewOptiBiotix Health PLC

OptiBiotix Health subsidiary signs Brazilian distribution deal

Ayalla Marketing, the company’s new partner, will distribute the cholesterol-reducing probiotic, LPLDL, as an ingredient and as four finished products

OptiBiotix Health PLC -

OptiBiotix Health PLC (LON:OPTI) said its subsidiary ProBiotix Health has signed an exclusive distribution agreement for Brazil with local group Ayalla Marketing.

The UK company’s new partner will distribute the cholesterol-reducing probiotic, LPLDL, both as an ingredient and as four finished products - CholBiome, CholBiomeX3, CholBiomeBP and CholBiome.

OptiBiotix said the deal offered an “agreed and expected” first order within 30 days from approval by the Brazilian authorities of its food technology.

The agreement is for an initial 12 months and there are “modest minimum order quantities for each product providing the company security of income and revenue growth”, investors were told.

“We chose Ayalla because of its reputation and expertise in commercialising pharmaceutical and non-drug products with strong science and clinical studies in the Brazilian market," Mikkel Hvid-Hansen, commercial director of ProBiotix Health said in a statement.

Founded in 1973, Ayalla started out providing active ingredients to the pharmaceutical industry.  Its portfolio now covers the veterinary, food, cosmetics and fragrance industries. 

Quick facts: OptiBiotix Health PLC

Price: 55.5 GBX

Market: AIM
Market Cap: £48.81 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...


OptiBiotix Health signs a sweet deal with US manufacturer to produce a line...

OptiBiotix Health PLC's (LON:OPTI) Stephen O'Hara talks to Proactive London about their deal with an unnamed US company to manufacture and commercialise a line of its SweetBiotix. The new partner has been granted an exclusive worldwide licence for the natural alternatives to sugar. In return,...

1 week, 6 days ago

2 min read